Modernization and Expansion of the University of Illinois at Chicago Animal-Based Research Program

摘要 伊利诺伊大学芝加哥分校(UIC)在健康差距研究方面开发了高度认可的项目 是城市公共机构中的全国领导者，通过以下方式为不同的患者群体提供护理 它的医院和基于社区的临床系统。我们的UIC研究项目是围绕我们的 多样化的人群和社区，专注于了解疾病机制，开发新的 治疗和改进与我们的患者基础相关的临床方法。我们的临床前模型 能力和实验动物研究设施现在需要扩展，以将我们的研究机会与 有能力生成和描述支持我们核心任务区的人类疾病模型。UIC 建议对动物研究项目进行关键的翻新，使其现代化，并扩大其动物研究项目 生物资源实验室(BRL)，该机构的中央动物设施。该项目将包括 翻新和升级供暖、通风和空调(暖通空调)的基本要素 BRL中的电气系统以增加住房容量并适应机构小鼠的增长- 基于癌症和新陈代谢研究计划。其中包括患者衍生的器官移植和异种移植。 使用未被充分代表的癌症患者群体的样本和一种新的新陈代谢的建模核心 疾病核心，以模拟心血管和代谢性疾病治疗中的健康差异。是这样的 现代化还将带来显著的能源效率。总体而言，UIC BRL的改进将支持 以动物为基础的研究，并允许扩大我们在健康方面的翻译和临床研究计划 差异和药物发现。UIC BRL扩展的长期影响将支持我们的计划 在健康差异研究和药物发现方面的卓越翻译，同时允许我们的NIH- 资助的基于人群的研究计划(我们所有人都在伊利诺伊州精密医学联盟，UIC 少数民族健康研究所和我们的CTSA支持的临床和翻译科学中心) 以及我们的爱荷华州立癌症中心。这一扩张还将影响我们地区合作伙伴的研究计划 依靠我们在动物研究方面的设施、核心和能力。最后，我们以创业为基础的战略 推动药物发现倡议的计划和营利性合作伙伴关系也迫使我们的 基于动物的临床前建模能力。

Abstract The University of Illinois at Chicago (UIC) has developed highly recognized programs in health disparity research and is a national leader among urban, public institutions that provide care for diverse patient populations through its hospital and community-based clinical systems. Our UIC research programs have developed around our diverse populations and communities with a focus on understanding disease mechanisms, developing novel therapeutics and refining clinical approaches that have relevance to our patient base. Our preclinical modeling capability and laboratory animal research facilities now require expansion to link our research opportunities with the capability to generate and characterize models of human disease that support our core mission areas. UIC proposes to modernize and expand its animal-based research programs by performing critical renovations to the Biologic Resources Laboratory (BRL), the institution’s centralized animal facility. The project will comprise renovations and upgrades to essential elements of the heating ventilation and air conditioning (HVAC) and electrical systems in the BRL to increase housing capacity and accommodate growth in the institution’s murine- based cancer and metabolic research programs. These include a patient-derived organoid and xenograft modeling core that uses samples from underrepresented cancer patient populations and a new Metabolic Disease Core to model health disparities in the treatment of cardiovascular and metabolic diseases. Such modernization will also result in significant energy efficiencies. Overall, UIC BRL improvements will support animal-based research and permit the expansion of our translational and clinical research programs in health disparities and drug discovery. The long-term impact of the UIC BRL expansion will sustain our programs of translational excellence in health disparities research and drug discovery while permitting the growth of our NIH- funded population-based research programs (All of Us within the Illinois Precision Medicine Consortium, UIC Institute for Minority Health Research, and our CTSA-supported Center for Clinical and Translational Sciences) and our UI Cancer Center. This expansion will also impact the research programs of our regional partners who rely upon our facilities, cores and capability in animal research. Finally, our entrepreneurship-based strategic plan and for-profit partnerships to drive drug discovery initiatives have also compelled the expansion of our animal-based preclinical modeling capabilities.